Annual Retained Earnings
-$1.56 B
-$327.26 M-26.50%
31 December 2023
Summary:
Allogene Therapeutics annual retained earnings is currently -$1.56 billion, with the most recent change of -$327.26 million (-26.50%) on 31 December 2023. During the last 3 years, it has fallen by -$915.89 million (-141.70%). ALLO annual retained earnings is now -6792217.39% below its all-time high of -$23.00 thousand, reached on 31 December 2017.ALLO Retained Earnings Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Retained Earnings
-$1.76 B
-$66.29 M-3.91%
30 September 2024
Summary:
Allogene Therapeutics quarterly retained earnings is currently -$1.76 billion, with the most recent change of -$66.29 million (-3.91%) on 30 September 2024. Over the past year, it has dropped by -$285.90 million (-19.40%). ALLO quarterly retained earnings is now -1179.71% below its all-time high of -$137.52 million, reached on 30 June 2018.ALLO Quarterly Retained Earnings Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ALLO Retained Earnings Performance
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | -26.5% | -19.4% |
3 y3 years | -141.7% | -112.4% |
5 y5 years | -638.5% | -425.2% |
ALLO Retained Earnings High & Low
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3 years | -141.7% | at low | -112.4% | at low |
5 y | 5 years | -638.5% | at low | -425.2% | at low |
alltime | all time | <-9999.0% | at low | -1179.7% | at low |
Allogene Therapeutics Retained Earnings History
Date | Annual | Quarterly |
---|---|---|
Sept 2024 | - | -$1.76 B(+3.9%) |
June 2024 | - | -$1.69 B(+4.1%) |
Mar 2024 | - | -$1.63 B(+4.2%) |
Dec 2023 | -$1.56 B(+26.5%) | -$1.56 B(+6.0%) |
Sept 2023 | - | -$1.47 B(+4.3%) |
June 2023 | - | -$1.41 B(+5.8%) |
Mar 2023 | - | -$1.33 B(+8.1%) |
Dec 2022 | -$1.23 B(+38.1%) | -$1.23 B(+8.2%) |
Sept 2022 | - | -$1.14 B(+7.9%) |
June 2022 | - | -$1.06 B(+7.6%) |
Mar 2022 | - | -$983.20 M(+9.9%) |
Dec 2021 | -$894.55 M | -$894.55 M(+8.0%) |
Sept 2021 | - | -$828.48 M(+10.4%) |
Date | Annual | Quarterly |
---|---|---|
June 2021 | - | -$750.29 M(+10.4%) |
Mar 2021 | - | -$679.36 M(+5.1%) |
Dec 2020 | -$646.34 M(+63.2%) | -$646.34 M(+11.9%) |
Sept 2020 | - | -$577.77 M(+12.9%) |
June 2020 | - | -$511.58 M(+13.5%) |
Mar 2020 | - | -$450.60 M(+13.8%) |
Dec 2019 | -$396.12 M(+87.3%) | -$396.12 M(+18.2%) |
Sept 2019 | - | -$335.09 M(+17.8%) |
June 2019 | - | -$284.36 M(+17.0%) |
Mar 2019 | - | -$243.11 M(+14.9%) |
Dec 2018 | -$211.53 M(>+9900.0%) | -$211.53 M(+16.9%) |
Sept 2018 | - | -$181.02 M(+31.6%) |
June 2018 | - | -$137.52 M |
Dec 2017 | -$23.00 K | - |
FAQ
- What is Allogene Therapeutics annual retained earnings?
- What is the all time high annual retained earnings for Allogene Therapeutics?
- What is Allogene Therapeutics annual retained earnings year-on-year change?
- What is Allogene Therapeutics quarterly retained earnings?
- What is the all time high quarterly retained earnings for Allogene Therapeutics?
- What is Allogene Therapeutics quarterly retained earnings year-on-year change?
What is Allogene Therapeutics annual retained earnings?
The current annual retained earnings of ALLO is -$1.56 B
What is the all time high annual retained earnings for Allogene Therapeutics?
Allogene Therapeutics all-time high annual retained earnings is -$23.00 K
What is Allogene Therapeutics annual retained earnings year-on-year change?
Over the past year, ALLO annual retained earnings has changed by -$327.26 M (-26.50%)
What is Allogene Therapeutics quarterly retained earnings?
The current quarterly retained earnings of ALLO is -$1.76 B
What is the all time high quarterly retained earnings for Allogene Therapeutics?
Allogene Therapeutics all-time high quarterly retained earnings is -$137.52 M
What is Allogene Therapeutics quarterly retained earnings year-on-year change?
Over the past year, ALLO quarterly retained earnings has changed by -$285.90 M (-19.40%)